Trinity Biotech plc (TRIB)
NASDAQ: TRIB · Real-Time Price · USD
7.23
-0.04 (-0.55%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Trinity Biotech Earnings Call Transcripts
Fiscal Year 2024
-
Q3 2024 saw 3% revenue growth, improved operating loss, and strong TrinScreen HIV sales. Transformation initiatives and new diagnostic acquisitions are expected to drive profitability and growth, with key product launches targeted for 2025–2026.
-
Q2 2024 saw 14% revenue growth, strong TrinScreen HIV sales, and improved operating loss. Transformation initiatives are driving cost reductions and margin improvements, with CGM development progressing toward pivotal trials and regulatory approval by end of 2025.